Bioorg. Med. bioorg. B Bi Bio Bioo BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 ...() 5 10 1 1 0 0 0
Available online available A Av Ava Avai BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 1 0 1 0 0 1
0968-0896/© 2024 0968-0896/© 0 09 096 0968 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 0 -/..(://.///./). 16 10 0 1 0 0 1
3-Tetrazolyl-β-carboline derivatives 3-tetrazolyl-β-carboline 3 3- 3-T 3-Te BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 0 --- 3 10 1 0 0 0 1
João L.P. joão J Jo Joã João BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 ..,,,,,..,, 11 10 1 0 0 0 1
M.V.D. Pinho m.v.d. M M. M.V M.V. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 ...,* 5 2 1 0 0 0 1
a University a a a a a BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 0 1 ,-,,-, 6 8 1 0 0 0 1
b UCIBIO b b b b b BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 0 1 -,,,,,, 7 10 1 0 0 0 1
c Associate c c c c c BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 0 1 -,,,, 5 7 1 0 0 0 1
d LAQV/REQUIMTE, d d d d d BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 0 1 /,,,,,,,- 9 9 1 0 0 0 1
313 Porto, 313 3 31 313 313 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 1 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 0 2 , 1 10 1 0 0 0 1
A R a A A A A BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 0 2 no 0 10 0 0 0 0 1
Keywords: Keywords: keywords: K Ke Key Keyw BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 : 1 4 0 0 0 0 1
β-Carbolines β-Carbolines β-carbolines β β- β-C β-Ca BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 2 - 1 5 0 0 0 0 1
Tetrazoles Tetrazoles tetrazoles T Te Tet Tetr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 2 no 0 4 0 0 0 0 1
Hetero-Diels-Alder Hetero-Diels-Alder hetero-diels-alder H He Het Hete BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 2 -- 2 8 0 0 0 0 1
Neuroprotective Agents neuroprotective N Ne Neu Neur BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 2 no 0 10 0 0 0 0 1
Parkinson's Disease parkinson's P Pa Par Park BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 2 ' 1 8 0 0 0 0 1
A B a A A A A BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 0 2 no 0 10 0 0 0 0 1
3-Tetrazolyl-β-carbolines were 3-tetrazolyl-β-carbolines 3 3- 3-T 3-Te BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 3 ---- 4 9 0 0 0 0 1
block, in block, b bl blo bloc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 ,.- 3 9 0 0 0 0 1
are often are a ar are are BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 ,--- 4 10 0 0 0 0 1
neuroprotective agents neuroprotective n ne neu neur BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 3 '. 2 9 0 0 0 0 1
against 1-methyl-4-phenylpyridin-1-ium against a ag aga agai BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 -----()- 8 9 0 0 0 0 1
relevant neuroprotective relevant r re rel rele BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 .,-(-----)--(-)- 16 9 0 0 0 0 1
β-carboline, stood β-carboline, β β- β-c β-ca BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 3 -,, 3 10 0 0 0 0 1
neurotoxin. The neurotoxin. n ne neu neur BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 3 . 1 9 0 0 0 0 1
(III)-induced cytotoxicity. (iii)-induced ( (I (II (III BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 3 ()-.,---- 9 9 0 0 0 0 1
cytotoxicity. Overall, cytotoxicity. c cy cyt cyto BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 3 .,--- 5 9 0 0 0 0 1
this finding this t th thi this BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 '. 2 7 0 0 0 0 1
1. Introduction 1. 1 1. 1. 1. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 5 . 1 10 0 0 0 0 1
β-Carbolines constitute β-carbolines β β- β-C β-Ca BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 5 - 1 8 0 0 0 0 1
compounds comprised compounds c co com comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 5 -- 2 8 0 0 0 0 1
pyrido[3,4-b]indole scaffold. pyrido[3,4-b]indole p py pyr pyri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 5 [,-].- 6 8 0 0 0 0 1
ities, 1,2 ities, i it iti itie BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 5 ,,-,,,- 7 10 0 0 0 0 1
among others. among a am amo amon BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 5 .- 2 2 0 0 0 0 1
In recent in I In In In BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 0 5 , 1 7 0 0 0 0 1
prepare new prepare p pr pre prep BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 5 -,- 3 8 0 0 0 0 1
β-carboline intermediates β-carboline β β- β-c β-ca BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 5 --,- 4 8 0 0 0 0 1
lowed by lowed l lo low lowe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 5 ,., 3 8 0 0 0 0 1
research group, research r re res rese BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 5 ,- 2 8 0 0 0 0 1
soalkenes toward soalkenes s so soa soal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 5 , 1 9 0 0 0 0 1
in the in i in in in BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 5 . 1 9 0 0 0 0 1
by treating by b by by by BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 7 - 1 10 0 1 0 0 1
hetero-Diels-Alder reactions hetero-diels-alder h he het hete BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 7 --.,- 5 9 0 1 0 0 1
undergo ring-opening undergo u un und unde BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 7 -- 2 9 0 1 0 0 1
oxime moiety. oxime o ox oxi oxim BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 7 .- 2 9 0 1 0 0 1
tryptamines. 6,7,17-19 tryptamines. t tr try tryp BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 7 .,,-,, 6 10 0 1 0 0 1
carboxylic acid carboxylic c ca car carb BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 8 , 1 9 0 0 0 0 1
synthesised and synthesised s sy syn synt BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 8 -- 2 10 0 0 0 0 1
razolyl-β-carbolines. 6,7 razolyl-β-carbolines. r ra raz razo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 8 --., 4 3 0 0 0 0 1
The synthesized the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 8 no 0 9 0 0 0 0 1
wide range wide w wi wid wide BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 8 .-, 3 10 0 0 0 0 1
for cancer for f fo for for BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 8 , 1 10 0 0 0 0 1
adenocarcinoma (PAN-1), adenocarcinoma a ad ade aden BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 9 (-),(), 7 8 0 0 0 0 1
(HEPG2) and (hepg2) ( (H (HE (HEP BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 9 ()(-).- 7 9 0 0 0 0 1
containing 3-tetrazolyl-β-carboline containing c co con cont BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 9 ---- 4 10 0 0 0 0 1
blastoma (U251), blastoma b bl bla blas BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 9 (),(-),- 8 9 0 0 0 0 1
noma (786-0), noma n no nom noma BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 0 9 (-),(-)(-) 10 8 0 0 0 0 1
tumour cell tumour t tu tum tumo BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 9 ()., 4 10 0 0 0 0 1
Within their within W Wi Wit With BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 10 , 1 9 0 0 0 0 1
synthetic and synthetic s sy syn synt BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 10 -- 2 9 0 0 0 0 1
pharmacological effects. pharmacological p ph pha phar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 10 ., 2 4 0 0 0 0 1
Parkinson's disease parkinson's P Pa Par Park BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 10 ' 1 9 0 0 0 0 1
the disruption the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 10 , 1 9 0 0 0 0 1
disorders, postural disorders, d di dis diso BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 10 ,,,. 4 10 0 0 0 0 1
condition is condition c co con cond BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 10 ,, 2 9 0 0 0 0 1
* Corresponding * * * * * BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 0 11 *. 2 4 0 1 0 0 1
E-mail address: e-mail E E- E-m E-ma BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 11 -:@..(....). 12 10 0 1 0 0 1
Contents lists contents C Co Con Cont BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 11 no 0 10 1 1 0 0 1
Bioorganic & bioorganic B Bi Bio Bioo BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 11 no 0 10 1 1 0 0 1
journal homepage: journal j jo jou jour BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 11 :..// 5 10 1 1 0 0 1
https://doi.org/10.1016/j.bmc.2024.117841 https://doi.org/10.1016/j.bmc.2024.117841 https://doi.org/10.1016/j.bmc.2024.117841 h ht htt http BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 1 0 11 ://././... 10 4 0 1 0 0 1
Received 12 received R Re Rec Rece BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 11 ;; 2 10 0 1 0 0 1
Bioorganic & bioorganic B Bi Bio Bioo BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 () 2 10 0 1 1 1 0
2 2 2 2 2 2 2 BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 0 0 no 0 10 0 1 0 0 0
greatly reduces greatly g gr gre grea BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 '.- 3 9 0 0 0 0 1
kinson's disease kinson's k ki kin kins BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 0 ', 2 9 0 0 0 0 1
aiming only aiming a ai aim aimi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 '. 2 9 0 0 0 0 1
Furthermore, some furthermore, F Fu Fur Furt BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 , 1 9 0 0 0 0 1
developing the developing d de dev deve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 , 1 9 0 0 0 0 1
be taken be b be be be BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 /. 2 8 0 0 0 0 1
Several studies several S Se Sev Seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 8 0 0 0 0 1
of β-carboline of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 -, 2 9 0 0 0 0 1
depression, 21-23 depression, d de dep depr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 ,-',-,,' 8 10 0 0 0 0 1
disease. 29-31 disease. d di dis dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 .- 2 1 0 0 0 0 1
In view in I In In In BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 0 0 - 1 8 0 0 0 0 1
neuropsychiatric diseases, neuropsychiatric n ne neu neur BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 0 ,--- 4 9 0 0 0 0 1
as potential as a as as as BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 ', 2 9 0 0 0 0 1
differentiated SH-SY5Y differentiated d di dif diff BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 -. 2 6 0 0 0 0 1
2. Results 2. 2 2. 2. 2. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 2 . 1 10 0 0 0 0 1
2.1. Chemistry 2.1. 2 2. 2.1 2.1. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 2 .. 2 10 0 0 0 0 1
Initially, the initially, I In Ini Init BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 2 ,- 2 9 0 0 0 0 1
viously described viously v vi vio viou BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 2 ., 2 9 0 0 0 0 1
4 was 4 4 4 4 4 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 1 2 ,- 2 9 0 0 0 0 1
mation, and mation, m ma mat mati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 2 ,-- 3 9 0 0 0 0 1
nitrosoalkene with nitrosoalkene n ni nit nitr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 2 ,--. 4 9 0 0 0 0 1
Reduction of reduction R Re Red Redu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 2 no 0 9 0 0 0 0 1
afforded the afforded a af aff affo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 .- 2 10 0 0 0 0 1
tetrazole 5 tetrazole t te tet tetr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 2 (-,-- 5 8 0 0 0 0 1
obenzaldehyde and obenzaldehyde o ob obe oben BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 2 -), 3 9 0 0 0 0 1
trifluoroacetic acid trifluoroacetic t tr tri trif BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 2 (),-- 5 9 0 0 0 0 1
ranging from ranging r ra ran rang BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 ().--- 6 9 0 1 0 0 1
were isolated were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 /,-- 4 9 0 1 0 0 1
lated as lated l la lat late BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 .-- 3 9 0 1 0 0 1
carried out carried c ca car carr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 , 1 9 0 1 0 0 1
affording β-carbolines affording a af aff affo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 --(-).- 7 9 0 1 0 0 1
were purified were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 , 1 10 0 1 0 0 1
overall efficiency overall o ov ove over BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 . 1 6 0 1 0 0 1
2.2. Biological 2.2. 2 2. 2.2 2.2. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 5 .. 2 10 0 1 0 0 1
2.2.1. Evaluation 2.2.1. 2 2. 2.2 2.2. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 5 ...' 4 6 0 0 0 0 1
The cytotoxicity the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 5 - 1 9 0 0 0 0 1
ated SH-SY5Y ated a at ate ated BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 5 -,, 3 9 0 0 0 0 1
red (NR) red r re red red BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 5 ()(). 5 9 0 0 0 0 1
Figure 2, figure F Fi Fig Figu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 5 , 1 9 0 0 0 0 1
tested compounds, tested t te tes test BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 5 , 1 10 0 0 0 0 1
concentrations equal concentrations c co con conc BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 ., 2 10 0 0 0 0 1
compound 1, compound c co com comp BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 ,.,. 4 10 0 0 0 0 1
65.9%, 24 65.9%, 6 65 65. 65.9 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 6 .,,,, 5 10 0 0 0 0 1
to control to t to to to BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 (). 3 10 0 0 0 0 1
were observed, were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 , 1 9 0 0 0 0 1
the two the t th the the BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 ( 1 10 0 0 0 0 1
74.0 and 74.0 7 74 74. 74.0 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 7 ..,)., 6 10 0 0 0 0 1
the results the t th the the BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 7 . 1 10 0 0 0 0 1
Indeed, in indeed, I In Ind Inde BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 7 ,, 2 9 0 0 0 0 1
significantly decreased significantly s si sig sign BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 7 .,.., 5 10 0 0 0 0 1
10, 25 10, 1 10 10, 10, BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 8 ,,., 4 10 0 0 0 0 1
62.2 and 62.2 6 62 62. 62.2 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 8 ..,. 4 9 0 0 0 0 1
compound 7a, compound c co com comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 8 , 1 9 0 0 0 0 1
exposure to exposure e ex exp expo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 8 , 1 9 0 0 0 0 1
uptake assay. uptake u up upt upta BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 8 .,- 3 9 0 0 0 0 1
tion was tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 8 no 0 9 0 0 0 0 1
(REZ reduction (rez ( (R (RE (REZ BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 8 (., 3 10 0 0 0 0 1
50 μM 50 5 50 50 50 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 1 9 ,). 3 10 0 0 0 0 1
compound 7b, compound c co com comp BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 9 , 1 10 0 0 0 0 1
reduction assay, reduction r re red redu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 9 , 1 10 0 0 0 0 1
the two the t th the the BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 9 ( 1 9 0 0 0 0 1
decreased to decreased d de dec decr BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 10 .. 2 10 0 0 0 0 1
compound 7b, compound c co com comp BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 10 ,).,, 5 9 0 0 0 0 1
compound 7b, compound c co com comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 10 , 1 10 0 0 0 0 1
reduction assay, reduction r re red redu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 10 , 1 9 0 0 0 0 1
exposure to exposure e ex exp expo BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 10 ( 1 9 0 0 0 0 1
decreased to decreased d de dec decr BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 11 .,). 4 10 0 0 0 0 1
Overall, compounds overall, O Ov Ove Over BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 11 ,,- 3 10 0 0 0 0 1
Figure 1. figure F Fi Fig Figu BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 11 .---- 5 10 0 0 0 0 1
cancer activity. cancer c ca can canc BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 11 . 1 2 0 0 0 0 1
Scheme 1. scheme S Sc Sch Sche BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 11 .---. 5 10 0 1 0 0 1
J.L.P. Ribeiro j.l.p. J J. J.L J.L. BLOCKSTART PAGEEND NEWFONT LOWERFONT 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 11 .... 4 10 0 1 1 1 0
Bioorganic & bioorganic B Bi Bio Bioo BLOCKSTART PAGESTART NEWFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 0 () 2 10 1 1 1 0 0
3 3 3 3 3 3 3 BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 1 1 no 0 10 1 1 0 0 0
Figure 2. figure F Fi Fig Figu BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 1 .-,()(), 8 10 1 1 0 0 1
exposure. Results exposure. e ex exp expo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 .,.- 4 9 1 1 0 0 1
ANOVA followed anova A AN ANO ANOV BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 1 '[***.;****..]. 15 6 1 1 0 0 1
J.L.P. Ribeiro j.l.p. J J. J.L J.L. BLOCKSTART PAGEEND NEWFONT LOWERFONT 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 11 .... 4 10 1 1 1 0 0
Bioorganic & bioorganic B Bi Bio Bioo BLOCKSTART PAGESTART NEWFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 0 () 2 10 0 0 1 0 0
4 4 4 4 4 4 4 BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 1 0 no 0 10 1 1 0 0 0
at concentrations at a at at at BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 , 1 9 0 0 0 0 1
highest concentration highest h hi hig high BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 -.- 3 10 0 0 0 0 1
trations were trations t tr tra trat BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 '- 2 9 1 1 0 0 1
roprotective effects. roprotective r ro rop ropr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 . 1 2 1 1 0 0 1
The ability the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 8 1 1 0 0 1
(ROS) overproduction (ros) ( (R (RO (ROS BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 0 ()., 4 9 1 1 0 0 1
as shown as a as as as BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 , 1 10 1 1 0 0 1
levels was levels l le lev leve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 - 1 9 1 1 0 0 1
tion of tion t ti tio tion BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 (,-,, 5 8 1 1 0 0 1
increased to increased i in inc incr BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 2 .,, 3 10 1 1 0 0 1
to control to t to to to BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 3 ). 2 10 1 1 0 0 1
2.2.2. Evaluation 2.2.2. 2 2. 2.2 2.2. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 3 ... 3 8 1 1 0 0 1
Neuroprotective effects neuroprotective N Ne Neu Neur BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 3 -. 2 8 1 1 0 0 1
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1 1- 1-M 1-Me BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 3 ----,,,-()- 11 9 1 1 0 0 1
dine analogue, dine d di din dine BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 3 ,- 2 10 1 1 0 0 1
1-methyl-4-phenyl-propionoxzy-piperidine. Once 1-methyl-4-phenyl-propionoxzy-piperidine. 1 1- 1-m 1-me BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 4 -----., 7 8 1 1 0 0 1
to its to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 ,--() 5 9 1 1 0 0 1
central nervous central c ce cen cent BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 (),-, 5 8 1 1 0 0 1
glial cells, glial g gl gli glia BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 4 ,,----,- 8 8 1 1 0 0 1
dihydropyridine (MPDP dihydropyridine d di dih dihy BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 4 (),- 4 9 1 1 0 0 1
lite, 1-methyl-4-phenylpyridin-1-ium lite, l li lit lite BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 4 ,-----(). 9 9 1 1 0 0 1
the brain, the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 , 1 9 1 1 0 0 1
toxic metabolite. toxic t to tox toxi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 .-, 3 9 1 1 0 0 1
where it where w wh whe wher BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 no 0 9 1 1 0 0 1
electron transport electron e el ele elec BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 -( 2 8 1 1 0 0 1
I), inhibiting i), I I) I), I), BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 4 ), 2 10 1 1 0 0 1
with ATP with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 ,- 2 9 1 1 0 0 1
cals. 38,39 cals. c ca cal cals BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 4 .,- 3 9 1 1 0 0 1
been commonly been b be bee been BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 no 0 9 1 1 0 0 1
agents, being agents, a ag age agen BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 ,,, 3 9 1 1 0 0 1
Parkinson's disease. parkinson's P Pa Par Park BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 4 '. 2 9 1 1 0 0 1
Figure 3. figure F Fi Fig Figu BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 9 .(),-,,- 8 10 1 1 0 0 1
probe. Results probe. p pr pro prob BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 .,.- 4 9 1 1 0 0 1
way ANOVA way w wa way way BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 2 9 '[****..]. 10 5 1 1 0 0 1
J.L.P. Ribeiro j.l.p. J J. J.L J.L. BLOCKSTART PAGEEND NEWFONT LOWERFONT 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 11 .... 4 10 0 0 1 0 0
Bioorganic & bioorganic B Bi Bio Bioo BLOCKSTART PAGESTART NEWFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 0 () 2 10 0 0 1 0 0
5 5 5 5 5 5 5 BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 2 0 no 0 10 1 1 0 0 0
MPP + mpp M MP MPP MPP BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 0 -,, 3 9 0 0 0 0 1
after exposure after a af aft afte BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 - 1 10 0 0 0 0 1
(up to (up ( (u (up (up BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 ()-- 4 9 0 0 0 0 1
trations of trations t tr tra trat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 (,.,).- 7 9 0 0 0 0 1
pounds were pounds p po pou poun BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 2 0 ,.,, 4 10 0 0 0 0 1
were also were w we wer were BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 10 0 0 0 0 1
concentration. As concentration. c co con conc BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 2 ., 2 10 1 1 0 0 1
effects were effects e ef eff effe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 2 , 1 10 1 1 0 0 1
MPP + mpp M MP MPP MPP BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 2 -, 2 10 1 1 0 0 1
concentration, for concentration, c co con conc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 2 ,, 2 10 1 1 0 0 1
cytotoxicity of cytotoxicity c cy cyt cyto BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 2 ., 2 9 1 1 0 0 1
NR uptake nr N NR NR NR BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 2 .,,. 4 9 1 1 0 0 1
exposure to exposure e ex exp expo BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 3 ,.- 3 10 1 1 0 0 1
pound 1, pound p po pou poun BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 3 ,,. 3 9 1 1 0 0 1
MPP + mpp M MP MPP MPP BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 4 . 1 10 1 1 0 0 1
highest concentration highest h hi hig high BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 , 1 10 0 0 0 0 1
increasing to increasing i in inc incr BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 .,.. 4 9 1 1 0 0 1
MPP + mpp M MP MPP MPP BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 4 ,.,, 4 9 1 1 0 0 1
when compared when w wh whe when BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 .. 2 9 1 1 0 0 1
compound 2, compound c co com comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 ,,- 3 9 1 1 0 0 1
fects were fects f fe fec fect BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 4 .( 2 9 1 1 0 0 1
significantly increased significantly s si sig sign BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 . 1 10 1 1 0 0 1
the presence the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 .,. 3 8 1 1 0 0 1
observed for observed o ob obs obse BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 ).,- 4 8 1 1 0 0 1
centration of centration c ce cen cent BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 7 , 1 9 1 1 0 0 1
MPP + mpp M MP MPP MPP BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 7 - 1 9 1 1 0 0 1
2, for 2, 2 2, 2, 2, BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 7 ,( 2 10 1 1 0 0 1
84.8, 83.4 84.8, 8 84 84. 84.8 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 7 .,.. 4 10 1 1 0 0 1
presence of presence p pr pre pres BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 ,.,, 4 9 1 1 0 0 1
compared to compared c co com comp BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 .). 3 9 1 1 0 0 1
Figure 4. figure F Fi Fig Figu BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 8 .-- 3 10 1 1 0 0 1
the presence the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 8 .,. 3 9 1 1 0 0 1
were performed were w we wer were BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 8 -'[##.;###.;####.. 18 9 1 1 0 0 1
MPP + mpp M MP MPP MPP BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 10 ;*.;**.;****.,[,(,.,)], 23 10 1 1 0 0 1
concentration]. concentration]. concentration]. c co con conc BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 11 ]. 2 10 1 1 0 0 1
J.L.P. Ribeiro j.l.p. J J. J.L J.L. BLOCKSTART PAGEEND NEWFONT LOWERFONT 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 11 .... 4 10 0 0 1 0 0
Bioorganic & bioorganic B Bi Bio Bioo BLOCKSTART PAGESTART NEWFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 0 () 2 10 0 0 1 0 0
6 6 6 6 6 6 6 BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 0 no 0 10 1 1 0 0 0
compounds 1 compounds c co com comp BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 , 1 10 0 0 0 0 1
on the on o on on on BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 ., 2 9 0 0 0 0 1
demonstrated the demonstrated d de dem demo BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 ,. 2 10 0 0 0 0 1
concentrations, against concentrations, c co con conc BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 1 ,- 2 9 1 1 0 0 1
toxin, with toxin, t to tox toxi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 1 ,-, 3 10 1 1 0 0 1
effect observed effect e ef eff effe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 1 .- 2 9 1 1 0 0 1
worthy, the worthy, w wo wor wort BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 1 , 1 9 1 1 0 0 1
the lowest the t th the the BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 ()()., 6 10 1 1 0 0 1
significantly increased significantly s si sig sign BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 .,.. 4 10 1 1 0 0 1
500 μM 500 5 50 500 500 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 2 ,., 3 10 1 1 0 0 1
respectively, when respectively, r re res resp BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 ,. 2 9 1 1 0 0 1
alone. Notably, alone. a al alo alon BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 3 .,- 3 10 1 1 0 0 1
tween differentiated tween t tw twe twee BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 3 - 1 9 1 1 0 0 1
presence of presence p pr pre pres BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 3 (), 3 10 1 1 0 0 1
which highlights which w wh whi whic BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 -- 2 10 1 1 0 0 1
induced cytotoxicity, induced i in ind indu BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 , 1 9 0 0 0 0 1
the aggressor. the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 . 1 9 0 0 0 0 1
concentration, NR concentration, c co con conc BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 ,.. 3 10 0 0 0 0 1
exposure to exposure e ex exp expo BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 . 1 10 0 0 0 0 1
7c, respectively, 7c, 7 7c 7c, 7c, BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 5 ,,. 3 9 0 0 0 0 1
alone. alone. alone. a al alo alon BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 . 1 0 1 1 0 0 1
The existence the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 6 - 1 8 1 1 0 0 1
pound 7c pound p po pou poun BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 -, 2 9 1 1 0 0 1
potentially including potentially p po pot pote BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 no 0 9 1 1 0 0 1
enhance energy enhance e en enh enha BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 , 1 9 1 1 0 0 1
concentration range concentration c co con conc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 - 1 9 1 1 0 0 1
nalling pathways, nalling n na nal nall BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 6 ,-, 3 9 1 1 0 0 1
redox balance redox r re red redo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 6 ., 2 8 1 1 0 0 1
recognized that recognized r re rec reco BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 no 0 8 1 1 0 0 1
tightly regulated tightly t ti tig tigh BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 ., 2 10 1 1 0 0 1
Figure 5. figure F Fi Fig Figu BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 8 .()-- 5 10 1 1 0 0 1
in the in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 3 8 .,.- 4 9 1 1 0 0 1
parisons were parisons p pa par pari BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 8 -'[###.;####.. 14 9 1 1 0 0 1
(III); *p (iii); ( (I (II (III BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 10 ();*.,[(),()(,.,)],()]. 23 10 1 1 0 0 1
J.L.P. Ribeiro j.l.p. J J. J.L J.L. BLOCKSTART PAGEEND NEWFONT LOWERFONT 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 11 .... 4 10 0 0 1 0 0
Bioorganic & bioorganic B Bi Bio Bioo BLOCKSTART PAGESTART NEWFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 0 () 2 10 0 1 1 0 0
7 7 7 7 7 7 7 BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 0 no 0 10 0 0 0 0 0
of compound of o of of of BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 no 0 8 0 1 0 0 1
balance and balance b ba bal bala BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 , 1 8 0 1 0 0 1
concentrations could concentrations c co con conc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 . 1 5 0 1 0 0 1
Overall, these overall, O Ov Ove Over BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 0 , 1 9 0 1 0 0 1
relevant neuroprotective relevant r re rel rele BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 no 0 8 0 1 0 0 1
neurotoxin that neurotoxin n ne neu neur BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 , 1 8 0 1 0 0 1
frequently used, frequently f fr fre freq BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 ,,- 3 9 0 1 0 0 1
drugs with drugs d dr dru drug BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 '. 2 7 0 1 0 0 1
Neuroprotective effects neuroprotective N Ne Neu Neur BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 0 ()-. 4 8 0 1 0 0 1
Iron is iron I Ir Iro Iron BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 0 no 0 8 0 1 0 0 1
human body. human h hu hum huma BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 . 1 9 0 1 0 0 1
its absorption, its i it its its BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 ,,,. 4 10 0 1 0 0 1
and neurodegenerative and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 .,- 3 9 0 1 0 0 1
lation of lation l la lat lati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 no 0 9 0 1 0 0 1
redox status redox r re red redo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 , 1 9 0 1 0 0 1
Fenton reaction fenton F Fe Fen Fent BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 3 0 , 1 9 0 1 0 0 1
the generation the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 •., 3 9 0 1 0 0 1
leads to leads l le lea lead BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 , 1 9 0 1 0 0 1
to be to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 . 1 9 0 1 0 0 1
study, the study, s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 ,()- 4 8 0 1 0 0 1
induced cytotoxicity induced i in ind indu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 ,, 2 9 0 1 0 0 1
exposure of exposure e ex exp expo BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 -( 2 9 0 1 0 0 1
1000 μM) 1000 1 10 100 1000 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 3 2 )- 2 10 0 0 0 0 1
the compounds the t th the the BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 (,.,). 6 8 0 0 0 0 1
promising compounds promising p pr pro prom BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 - 1 9 0 0 0 0 1
induced cell induced i in ind indu BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 ,,. 3 10 0 0 0 0 1
were tested were w we wer were BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 ,., 3 10 0 0 0 0 1
given the given g gi giv give BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 ., 2 9 0 0 0 0 1
observed in observed o ob obs obse BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 , 1 9 0 0 0 0 1
iron-induced cytotoxicity, iron-induced i ir iro iron BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 -, 2 9 0 0 0 0 1
only for only o on onl only BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 no 0 10 0 0 0 0 1
the lowest the t th the the BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 .,- 3 8 0 0 0 0 1
cantly increased cantly c ca can cant BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 3 .() 3 10 0 0 0 0 1
presence of presence p pr pre pres BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 3 ,. 2 8 0 0 0 0 1
exposure to exposure e ex exp expo BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 (). 3 10 0 0 0 0 1
were detected were w we wer were BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 (),, 4 10 0 0 0 0 1
2.5 or 2.5 2 2. 2.5 2.5 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 3 .,()- 5 10 0 0 0 0 1
tration was tration t tr tra trat BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 . 1 6 0 0 0 0 1
Overall, and overall, O Ov Ove Over BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 4 ,,-- 4 8 0 0 0 0 1
razolyl-β-carbolines demonstrated razolyl-β-carbolines r ra raz razo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 --, 3 9 0 0 0 0 1
counteracting the counteracting c co cou coun BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 no 0 9 0 0 0 0 1
mimic pathophysiological mimic m mi mim mimi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 '. 2 9 0 0 0 0 1
accepted that accepted a ac acc acce BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 no 0 9 0 0 0 0 1
oxidative stress, oxidative o ox oxi oxid BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 ,,., 4 9 0 0 0 0 1
MPP + mpp M MP MPP MPP BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 4 , 1 9 0 0 0 0 1
leading to leading l le lea lead BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 , 1 8 0 0 0 0 1
ultimately resulting ultimately u ul ult ulti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 ., 2 5 0 0 0 0 1
Iron accumulation iron I Ir Iro Iron BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 4 no 0 8 0 0 0 0 1
disease and disease d di dis dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 ', 2 10 0 0 0 0 1
the substantia the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 . 1 9 0 0 0 0 1
death through death d de dea deat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 , 1 8 0 0 0 0 1
death characterized death d de dea deat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 -. 2 8 0 0 0 0 1
hallmarks of hallmarks h ha hal hall BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 - 1 9 0 0 0 0 1
generative diseases generative g ge gen gene BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 '. 2 7 0 0 0 0 1
However, it however, H Ho How Howe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 4 ,-- 3 8 0 0 0 0 1
β-carbolines demonstrated β-carbolines β β- β-c β-ca BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 - 1 8 0 0 0 0 1
cells against cells c ce cel cell BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 -,- 3 9 0 0 0 0 1
protective effects protective p pr pro prot BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 -.- 3 9 0 0 0 0 1
gests that gests g ge ges gest BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 --- 3 9 0 0 0 0 1
more potent more m mo mor more BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 - 1 9 0 0 0 0 1
induced mitochondrial induced i in ind indu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 (.. 3 9 0 0 0 0 1
mitochondrial function, mitochondrial m mi mit mito BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 ,, 2 9 0 0 0 0 1
survival pathways) survival s su sur surv BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 )-. 3 7 0 0 0 0 1
3. Conclusion 3. 3 3. 3. 3. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 6 . 1 10 0 1 0 0 1
The synthesis the T Th The The BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 6 ---- 4 9 0 1 0 0 1
roprotective agents roprotective r ro rop ropr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 6 '. 2 10 0 1 0 0 1
synthetic strategy synthetic s sy syn synt BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 no 0 10 0 1 0 0 1
hetero-Diels-Alder reaction hetero-diels-alder h he het hete BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 6 --,---(-- 9 9 0 1 0 0 1
sovinyl)-1H-tetrazole, and sovinyl)-1h-tetrazole, s so sov sovi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 6 )--,- 5 10 0 1 0 0 1
Spengler reaction spengler S Sp Spe Spen BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 6 no 0 9 0 1 0 0 1
step. step. step. s st ste step BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 . 1 0 0 1 0 0 1
The 3-tetrazolyl-β-carbolines the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 6 --- 3 9 0 1 0 0 1
against differentiated against a ag aga agai BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 -,- 3 10 0 1 0 0 1
istics, through istics, i is ist isti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 6 ,( 2 9 0 1 0 0 1
resazurin reduction resazurin r re res resa BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 6 ) 1 10 0 1 0 0 1
studied compounds studied s st stu stud BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 - 1 10 0 0 0 0 1
whereas for whereas w wh whe wher BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 - 1 10 0 0 0 0 1
cytotoxic is cytotoxic c cy cyt cyto BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 7 . 1 10 0 0 0 0 1
The evaluation the T Th The The BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 7 ' 1 8 0 0 0 0 1
study of study s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 -, 2 10 0 0 0 0 1
neurotoxin used neurotoxin n ne neu neur BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 7 '.- 3 9 0 0 0 0 1
SY5Y cells sy5y S SY SY5 SY5Y BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 7 no 0 8 0 0 0 0 1
under investigation, under u un und unde BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 ,--- 4 9 0 0 0 0 1
significant reduction significant s si sig sign BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 . 1 9 0 0 0 0 1
most promising most m mo mos most BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 ,-(-----)--(-- 14 8 0 0 0 0 1
thylaminophenyl)-β-carboline, led thylaminophenyl)-β-carboline, t th thy thyl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 7 )--,- 5 8 0 0 0 0 1
induced cytotoxicity, induced i in ind indu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 , 1 9 0 0 0 0 1
the aggressor, the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 , 1 9 0 0 0 0 1
aggressor. aggressor. aggressor. a ag agg aggr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 . 1 1 0 0 0 0 1
The compounds the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 7 no 0 8 0 0 0 0 1
against MPP against a ag aga agai BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 -- 2 9 0 0 0 0 1
protective effect protective p pr pro prot BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 ()-., 5 9 0 0 0 0 1
one 3-tetrazolyl-β-carboline one o on one one BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 ---- 4 9 0 0 0 0 1
cytotoxicity, although cytotoxicity, c cy cyt cyto BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 7 , 1 9 0 0 0 0 1
the lowest the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 no 0 9 0 0 0 0 1
lowest concentration lowest l lo low lowe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 . 1 5 0 0 0 0 1
Overall, our overall, O Ov Ove Over BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 7 , 1 9 0 0 0 0 1
new 3-tetrazolyl-β-carbolines. new n ne new new BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 ---.,-- 7 9 0 0 0 0 1
β-carbolines significantly β-carbolines β β- β-c β-ca BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 7 --- 3 9 0 0 0 0 1
SY5Y cells, sy5y S SY SY5 SY5Y BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 7 , 1 8 0 0 0 0 1
reduction in reduction r re red redu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 -.-- 4 9 0 0 0 0 1
razolyl-β-carbolines may razolyl-β-carbolines r ra raz razo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 7 -- 2 9 0 0 0 0 1
effectively counteract effectively e ef eff effe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 - 1 9 0 0 0 0 1
oxidative stress oxidative o ox oxi oxid BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 7 (..,- 5 9 0 0 0 0 1
tive damage, tive t ti tiv tive BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 7 ,)- 3 8 0 0 0 0 1
mediated toxicity. mediated m me med medi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 . 1 9 0 0 0 0 1
targets and targets t ta tar targ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 , 1 8 0 0 0 0 1
evidence that evidence e ev evi evid BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 --- 3 9 0 0 0 0 1
neuroprotective agents neuroprotective n ne neu neur BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 7 ', 2 9 0 0 0 0 1
inspire the inspire i in ins insp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 '.- 3 9 0 0 0 0 1
fore, further fore, f fo for fore BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 , 1 9 0 0 0 0 1
elucidate the elucidate e el elu eluc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 ()-- 4 8 0 0 0 0 1
zolyl-β-carbolines-mediated neuroprotection. zolyl-β-carbolines-mediated z zo zol zoly BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 7 ---. 4 6 0 0 0 0 1
4. Experimental 4. 4 4. 4. 4. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 10 . 1 10 0 0 0 0 1
4.1. Chemistry 4.1. 4 4. 4.1 4.1. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 10 .. 2 10 0 0 0 0 1
4.1.1. General 4.1.1. 4 4. 4.1 4.1. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 10 ... 3 3 0 0 0 0 1
Nuclear Magnetic nuclear N Nu Nuc Nucl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 10 () 2 8 0 0 0 0 1
Bruker Avance bruker B Br Bru Bruk BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 10 () 2 9 0 0 0 0 1
( 13 ( ( ( ( ( BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 4 10 ().- 4 10 0 0 0 0 1
thylsilane (TMS) thylsilane t th thy thyl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 10 (),() 5 9 0 0 0 0 1
expressed in expressed e ex exp expr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 10 .() 3 9 0 0 0 0 1
Transform spectrometer transform T Tr Tra Tran BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 10 no 0 8 0 0 0 0 1
Reflectance (ATR) reflectance R Re Ref Refl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 10 ().- 4 9 0 0 0 0 1
(HRMS) were (hrms) ( (H (HR (HRM BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 10 () 2 8 0 0 0 0 1
electrospray ionization electrospray e el ele elec BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 10 (). 3 9 0 0 0 0 1
J.L.P. Ribeiro j.l.p. J J. J.L J.L. BLOCKSTART PAGEEND SAMEFONT LOWERFONT 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 11 .... 4 10 0 1 1 0 0
Bioorganic & bioorganic B Bi Bio Bioo BLOCKSTART PAGESTART NEWFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 0 () 2 10 0 1 1 0 0
8 8 8 8 8 8 8 BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 0 no 0 10 0 0 0 0 0
glass capillaries. glass g gl gla glas BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 5 0 .() 3 8 0 1 0 0 1
using precoated using u us usi usin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 . 1 9 0 1 0 0 1
using silica using u us usi usin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 .-- 3 10 0 1 0 0 1
β-carbolines 1 β-carbolines β β- β-c β-ca BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 -. 2 9 0 1 0 0 1
4.1.2. General 4.1.2. 4 4. 4.1 4.1. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 0 ...-- 5 9 0 0 0 0 1
Trifluoroacetic acid trifluoroacetic T Tr Tri Trif BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 0 ()( 3 9 0 0 0 0 1
equiv) and equiv) e eq equ equi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 )() 3 9 0 0 0 0 1
(23 mL/mmol). (23 ( (2 (23 (23 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 0 (/)., 5 9 0 0 0 0 1
and monitored and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 . 1 8 0 0 0 0 1
completion, the completion, c co com comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 , 1 8 0 0 0 0 1
pressure, the pressure, p pr pre pres BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ,() 3 10 0 0 0 0 1
with an with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 . 1 9 0 0 0 0 1
extracted with extracted e ex ext extr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 (), 3 10 0 0 0 0 1
and the and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 .- 2 9 0 0 0 0 1
tallization in tallization t ta tal tall BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 /,- 3 9 0 0 0 0 1
less otherwise less l le les less BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 . 1 3 0 0 0 0 1
4.1.2.1. 3-(1-Benzyl-1H-tetrazol-5-yl)-1-(m-nitrophenyl)-2,3,4,9-tetrahy- 4.1.2.1. 4 4. 4.1 4.1. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 1 ....-(-----)--(-)-,,,-- 23 9 0 0 0 0 1
dro-β-carboline (6a). dro-β-carboline d dr dro dro- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 1 --(). 5 8 0 0 0 0 1
(0.20 mmol, (0.20 ( (0 (0. (0.2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 1 (.,)-(.,) 9 8 0 0 0 0 1
described in described d de des desc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 1 (:), 4 10 0 0 0 0 1
cis/trans isomers cis/trans c ci cis cis/ BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 1 /[,,(:)].(-): 13 9 0 0 0 0 1
(ATR) ν: (atr) ( (A (AT (ATR BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 1 ():,,,,,,,-. 12 10 0 0 0 0 1
(Acetone-d 6 (acetone-d ( (A (Ac (Ace BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 1 (-):.(,.,.,),.-.(,),. 21 10 0 0 0 0 1
(ddd, J (ddd, ( (d (dd (ddd BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 1 (,.,.,.,),.(,.,),.(, 20 9 0 0 0 0 1
J = j J J J J BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 5 1 .,),.(,.,),.-.(,),.-. 21 9 0 0 0 0 1
(m, 8H), (m, ( (m (m, (m, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 1 (,),.-.(,),.-.(,),.-.(,), 25 8 0 0 0 0 1
8.10-8.11 (m, 8.10-8.11 8 8. 8.1 8.10 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 1 .-.(,),.-.(,),.(,).(-) 22 9 0 0 0 0 1
m/z for m/z m m/ m/z m/z BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 1 /[]..,.. 8 9 0 0 0 0 1
4.1.2.2. 3-(1-Benzyl-1H-tetrazol-5-yl)-1-(o-chlorophenyl)-2,3,4,9-tetra- 4.1.2.2. 4 4. 4.1 4.1. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 2 ....-(-----)--(-)-,,,-- 23 10 0 0 0 0 1
hydro-β-carboline (6b). hydro-β-carboline h hy hyd hydr BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 2 --(). 5 8 0 0 0 0 1
(0.16 mmol, (0.16 ( (0 (0. (0.1 BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 2 (.,)-(.,) 9 10 0 0 0 0 1
described in described d de des desc BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 2 (:), 4 10 0 0 0 0 1
cis/trans isomers cis/trans c ci cis cis/ BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 2 /[,,(:)].-:():,, 16 10 0 0 0 0 1
1016, 1319, 1016, 1 10 101 1016 BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 5 3 ,,,-.(-):.-.(, 14 9 0 0 0 0 1
2H), 4.21 2h), 2 2H 2H) 2H), BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 3 ),.(,.,.,.,),.(,.,), 20 10 0 0 0 0 1
5.54 (d, 5.54 5 5. 5.5 5.54 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 3 .(,.,),.(,.,),.-.(,), 21 10 0 0 0 0 1
6.97-7.41 (m, 6.97-7.41 6 6. 6.9 6.97 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 3 .-.(,),.-.(,),.(,).(-) 22 9 0 0 0 0 1
m/z for m/z m m/ m/z m/z BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 3 /[]..,.. 8 9 0 0 0 0 1
4.1.2.3. 3-(1-Benzyl-1H-tetrazol-5-yl)-1-(p-dimethylaminophenyl)- 4.1.2.3. 4 4. 4.1 4.1. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 3 ....-(-----)--(-)- 18 8 0 0 0 0 1
2,3,4,9-tetrahydro-β-carboline (6c). 2,3,4,9-tetrahydro-β-carboline 2 2, 2,3 2,3, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 3 ,,,---(). 9 10 0 0 0 0 1
5 (0.16 5 5 5 5 5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 3 (.,)-(., 8 9 0 0 0 0 1
34 mg), 34 3 34 34 34 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 3 ),(:), 6 9 0 0 0 0 1
the trans-6c the t th the the BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 -[,].():,,,, 12 10 0 0 0 0 1
1495, 1521, 1495, 1 14 149 1495 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 5 4 ,,-.(-):.(,),.(, 16 9 0 0 0 0 1
J = j J J J J BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 5 4 .,.,),.(,.,.,),.(, 18 9 0 0 0 0 1
J = j J J J J BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 5 4 .,.,.,),.(,.,),.(, 18 8 0 0 0 0 1
J = j J J J J BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 5 4 .,),.(,.,),.-.(,), 18 8 0 0 0 0 1
6.97-7.08 (m, 6.97-7.08 6 6. 6.9 6.97 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 4 .-.(,),.-.(,),.-.(,),.(, 24 8 0 0 0 0 1
J = j J J J J BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 5 4 .,),.(,).(-):.,.,., 19 10 0 0 0 0 1
48.6, 49.8, 48.6, 4 48 48. 48.6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 4 .,.,.,.,.,.,.,.,.,.,., 22 10 0 0 0 0 1
128.2, 128.6, 128.2, 1 12 128 128. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 4 .,.,.,.,.,.,.,..(-) 19 9 0 0 0 0 1
m/z for m/z m m/ m/z m/z BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 4 /[-]..,.. 9 8 0 0 0 0 1
4.1.3. General 4.1.3. 4 4. 4.1 4.1. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 ...- 4 8 0 0 0 0 1
Sulphur powder sulphur S Su Sul Sulp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 5 () 2 9 0 0 0 0 1
tetrahydro-β-carboline 6 tetrahydro-β-carboline t te tet tetr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 --()(/ 6 8 0 0 0 0 1
mmol). The mmol). m mm mmo mmol BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 ).. 3 10 0 0 0 0 1
time, the time, t ti tim time BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 ,. 2 9 0 0 0 0 1
addition of addition a ad add addi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 ,, 2 9 0 0 0 0 1
products in products p pr pro prod BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 ,. 2 6 0 0 0 0 1
4.1.3.1. 3-(1-Benzyl-1H-tetrazol-5-yl)-1-(m-nitrophenyl)-β-carboline 4.1.3.1. 4 4. 4.1 4.1. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 ....-(-----)--(-)-- 19 9 0 1 0 0 1
(7a). Obtained (7a). ( (7 (7a (7a) BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 ().--(.,), 10 9 0 1 0 0 1
described in described d de des desc BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 ,-(,). 6 10 0 1 0 0 1
mp 275.3-277.2 mp m mp mp mp BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 6 .-.•().():,,, 13 10 0 1 0 0 1
1079, 1343, 1079, 1 10 107 1079 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 6 6 ,,,-.(-):.(,), 14 9 0 1 0 0 1
7.18-7.21 (m, 7.18-7.21 7 7. 7.1 7.18 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 6 .-.(,),.-.(,),.(,.,.,., 23 9 0 1 0 0 1
1H), 7.64-7.72 1h), 1 1H 1H) 1H), BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 6 ),.-.(,),.(,.,),.(,., 21 9 0 1 0 0 1
1.2 Hz, 1.2 1 1. 1.2 1.2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 6 .,),.(,.,.,.,),.(,., 20 10 0 1 0 0 1
1H), 8.72 1h), 1 1H 1H) 1H), BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 6 ),.(,.,),.(,),.(,). 19 9 0 1 0 0 1
(DMSO-d 6 (dmso-d ( (D (DM (DMS BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 6 (-):.,.,.,.,.,.,.,., 20 9 0 1 0 0 1
127.1, 127.9, 127.1, 1 12 127 127. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 6 .,.,.,.,.,.,.,.,.,., 20 9 0 1 0 0 1
138.6, 139.8, 138.6, 1 13 138 138. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 6 .,.,.,.,..(-)/ 14 8 0 1 0 0 1
C 25 c C C C C BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 6 6 []..,.. 7 8 0 1 0 0 1
4.1.3.2. 3-(1-Benzyl-1H-tetrazol-5-yl)-1-(o-chlorophenyl)-β-carboline 4.1.3.2. 4 4. 4.1 4.1. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 7 ....-(-----)--(-)-- 19 10 0 0 0 0 1
(7b). Obtained (7b). ( (7 (7b (7b) BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 7 ().--(.,), 10 9 0 0 0 0 1
described in described d de des desc BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 7 ,(,). 5 10 0 0 0 0 1
234.4-236.0 • 234.4-236.0 2 23 234 234. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 7 .-.•().():,,,, 14 10 0 0 0 0 1
1436, 1451 1436, 1 14 143 1436 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 6 7 ,-.(-):.(,),.-.(, 17 9 0 0 0 0 1
3H), 7.24-7.26 3h), 3 3H 3H) 3H), BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 7 ),.-.(,),.(,.,.,.,),.-. 23 9 0 0 0 0 1
(m, 4H), (m, ( (m (m, (m, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 7 (,),.-.(,),.(,.,.,),.(,), 25 10 0 0 0 0 1
10.93 (br 10.93 1 10 10. 10.9 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 7 .(,).(-):.,.,.,., 17 9 0 0 0 0 1
122.4, 123.1, 122.4, 1 12 122 122. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 7 .,.,.,.,.,.,.,.,.,., 20 9 0 0 0 0 1
133.9, 134.5, 133.9, 1 13 133 133. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 7 .,.,.,.,.,.,.,..(-) 19 9 0 0 0 0 1
m/z for m/z m m/ m/z m/z BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 7 /[]..,.. 8 9 0 0 0 0 1
4.1.3.3. 3-(1-Benzyl-1H-tetrazol-5-yl)-1-(p-dimethylaminophenyl)-β-car- 4.1.3.3. 4 4. 4.1 4.1. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 8 ....-(-----)--(-)--- 20 9 0 0 0 0 1
boline (7c). boline b bo bol boli BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 8 ().--(., 8 9 0 0 0 0 1
40 mg), 40 4 40 40 40 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 8 ),,(, 5 10 0 0 0 0 1
56%). mp 56%). 5 56 56% 56%) BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 9 )..-.•().():,, 14 10 0 0 0 0 1
846, 1091, 846, 8 84 846 846, BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 9 ,,,,-.(-):.(,), 15 9 0 0 0 0 1
6.49 (s, 6.49 6 6. 6.4 6.49 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 9 .(,),.-.(,),.-.(,),.(,., 24 9 0 0 0 0 1
6.8, 0.8 6.8, 6 6. 6.8 6.8, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 9 .,.,),.(,.,.,.,),.(,., 22 10 0 0 0 0 1
1H), 7.90-7.94 1h), 1 1H 1H) 1H), BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 9 ),.-.(,),.(,.,),.(,),.( 23 9 0 0 0 0 1
s, 1H). s, s s, s, s, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 9 ,).(-):.,.,.,.,.,., 19 9 0 0 0 0 1
120.6, 121.0, 120.6, 1 12 120 120. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 9 .,.,.,.,.,.,.,.,.,., 20 9 0 0 0 0 1
132.7, 133.1, 132.7, 1 13 132 132. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 9 .,.,.,.,.,..(-)/ 16 8 0 0 0 0 1
C 27 c C C C C BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 6 9 []..,.. 7 7 0 0 0 0 1
4.2. Biological 4.2. 4 4. 4.2 4.2. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 10 .. 2 10 0 0 0 0 1
4.2.1. Materials 4.2.1. 4 4. 4.2 4.2. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 10 ... 3 2 0 0 0 0 1
The human the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 10 - 1 9 0 0 0 0 1
American Type american A Am Ame Amer BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 10 (;,,).- 7 10 0 0 0 0 1
biotic mixture biotic b bi bio biot BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 10 (/,/), 6 10 0 0 0 0 1
non-essential amino non-essential n no non non- BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 10 -()' 4 8 0 0 0 0 1
(HBSS) with (hbss) ( (H (HB (HBS BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 7 10 ()[(/) 6 8 0 0 0 0 1
(-/-), respectively] (-/-), ( (- (-/ (-/- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 7 10 (-/-),](). 10 8 0 0 0 0 1
inactivated fetal inactivated i in ina inac BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 10 ()( 3 9 0 0 0 0 1
Kingdom). Dulbecco's kingdom). K Ki Kin King BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 10 ).'' 4 8 0 0 0 0 1
sodium bicarbonate, sodium s so sod sodi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 10 ,- 2 9 0 0 0 0 1
(EDTA) solution (edta) ( (E (ED (EDT BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 7 10 ()(./),-- 9 8 0 0 0 0 1
acetate (TPA), acetate a ac ace acet BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 10 (),(),(),--- 12 9 0 0 0 0 1
phenylpyridinium (MPP phenylpyridinium p ph phe phen BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 10 (),()(), 8 10 0 0 0 0 1
acid disodium acid a ac aci acid BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 10 (), 3 9 0 0 0 0 1
(Na 3 (na ( (N (Na (Na BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 10 (),,-(-),-- 11 9 0 0 0 0 1
droperoxide (t-BHP) droperoxide d dr dro drop BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 10 (-)()- 6 9 0 0 0 0 1
Aldrich (Germany). aldrich A Al Ald Aldr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 7 10 ().() 5 8 0 0 0 0 1
Merck (Darmstadt, merck M Me Mer Merc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 10 (,). 4 9 0 0 0 0 1
used was used u us use used BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 10 (,,).- 6 9 0 0 0 0 1
fied water fied f fi fie fied BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 10 no 0 9 0 0 0 0 1
Direct-Q® Ultrapure direct-q® D Di Dir Dire BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 10 -,(,- 5 8 0 0 0 0 1
many). All many). m ma man many BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 10 ). 2 9 0 0 0 0 1
grade available. grade g gr gra grad BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 10 . 1 2 0 0 0 0 1
J.L.P. Ribeiro j.l.p. J J. J.L J.L. BLOCKSTART PAGEEND NEWFONT LOWERFONT 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 7 11 .... 4 10 0 1 1 0 0
Bioorganic & bioorganic B Bi Bio Bioo BLOCKSTART PAGESTART NEWFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 0 () 2 10 0 1 1 0 0
9 9 9 9 9 9 9 BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 7 0 no 0 10 0 0 0 0 0
4.2.2. Methods 4.2.2. 4 4. 4.2 4.2. BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 1 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 ... 3 1 0 1 0 0 1
SH-SY5Y cells sh-sy5y S SH SH- SH-S BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 -- 2 6 0 1 0 0 1
The SH-SY5Y the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 0 - 1 7 0 1 0 0 1
several protocols several s se sev seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 , 1 9 0 1 0 0 1
cells to cells c ce cel cell BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 ,- 2 9 0 1 0 0 1
opment of opment o op opm opme BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 -,- 3 9 0 1 0 0 1
apses, heightened apses, a ap aps apse BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 ,, 2 9 0 1 0 0 1
induction of induction i in ind indu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 -,,- 4 8 0 1 0 0 1
transmitter receptors. transmitter t tr tra tran BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 .,- 3 10 0 1 0 0 1
was induced was w wa was was BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 8 0 1 0 0 1
acid (RA) acid a ac aci acid BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 ()----(), 9 9 0 1 0 0 1
well-established protocol. well-established w we wel well BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 -. 2 9 0 1 0 0 1
of SH-SY5Y of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 -, 2 8 0 1 0 0 1
significant increase significant s si sig sign BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 () 2 9 0 1 0 0 1
tyrosine hydroxylase tyrosine t ty tyr tyro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 (). 3 3 0 1 0 0 1
The cells the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 0 , 1 8 0 1 0 0 1
Dulbecco's Modified dulbecco's D Du Dul Dulb BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 0 ''. 3 8 0 1 0 0 1
glucose, supplemented glucose, g gl glu gluc BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 ,(),- 5 8 0 1 0 0 1
biotic mixture biotic b bi bio biot BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 1 (//), 5 10 0 0 0 0 1
1% MEM 1% 1 1% 1% 1% BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 1 -. 2 8 0 0 0 0 1
controlled environment controlled c co con cont BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 no 0 9 0 0 0 0 1
37 • 37 3 37 37 37 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 1 •. 2 9 0 0 0 0 1
80-90%, cultures 80-90%, 8 80 80- 80-9 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 1 -,(./ 5 9 0 0 0 0 1
1 mM 1 1 1 1 1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 7 1 ).,- 4 9 0 0 0 0 1
well plates well w we wel well BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 ,/.- 4 10 0 0 0 0 1
tiation, the tiation, t ti tia tiat BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 1 ,- 2 9 0 0 0 0 1
taining RA taining t ta tai tain BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 2 ., 2 10 0 0 0 0 1
added to added a ad add adde BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 no 0 9 0 0 0 0 1
cell differentiation. cell c ce cel cell BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 ., 2 9 0 0 0 0 1
experiments. The experiments. e ex exp expe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 . 1 9 0 0 0 0 1
the 20th the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 . 1 3 0 0 0 0 1
Evaluation of evaluation E Ev Eva Eval BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 2 '. 2 5 0 0 0 0 1
The cytotoxicity the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 2 - 1 8 0 0 0 0 1
SY5Y cells sy5y S SY SY5 SY5Y BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 2 ,() 3 9 0 0 0 0 1
and neutral and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 ,, 2 9 0 0 0 0 1
cytotoxic concentrations cytotoxic c cy cyt cyto BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 2 no 0 9 0 0 0 0 1
neuroprotective effects. neuroprotective n ne neu neur BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 2 .,,- 4 10 0 0 0 0 1
entiated SH-SY5Y entiated e en ent enti BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 2 - 1 9 0 0 0 0 1
compounds under compounds c co com comp BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 3 ,, 2 10 0 0 0 0 1
24 h, 24 2 24 24 24 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 3 ,•-.- 5 9 0 0 0 0 1
(1%) was (1%) ( (1 (1% (1%) BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 3 (). 3 4 0 0 0 0 1
Resazurin reduction resazurin R Re Res Resa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 3 . 1 3 0 0 0 0 1
The resazurin the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 3 () 2 9 0 0 0 0 1
variety of variety v va var vari BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 3 ,, 2 9 0 0 0 0 1
cell proliferation, cell c ce cel cell BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 3 ,. 2 9 0 0 0 0 1
of the of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 3 - 1 9 0 0 0 0 1
lular conversion lular l lu lul lula BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 3 . 1 9 0 0 0 0 1
Initially, the initially, I In Ini Init BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 3 ,- 2 10 0 0 0 0 1
with minimal with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 3 . 1 9 0 0 0 0 1
membranes, it membranes, m me mem memb BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 3 , 1 8 0 0 0 0 1
fluorescent, pink-coloured fluorescent, f fl flu fluo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 3 ,-,, 4 9 0 0 0 0 1
to traverse to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 3 . 1 9 0 0 0 0 1
indicative of indicative i in ind indi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 3 ., 2 9 0 0 0 0 1
After exposure after A Af Aft Afte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 3 - 1 8 0 0 0 0 1
24 h, 24 2 24 24 24 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 3 , 1 9 0 0 0 0 1
with REZ with w wi wit with BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 4 (/,),•, 7 10 0 0 0 0 1
a humidified a a a a a BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 8 5 -,.- 4 9 0 0 0 0 1
rescence was rescence r re res resc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 ( 1 9 0 0 0 0 1
BioTek Instruments, biotek B Bi Bio BioT BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 ,,), 4 8 0 0 0 0 1
wavelengths of wavelengths w wa wav wave BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 ,. 2 9 0 0 0 0 1
reduction relative reduction r re red redu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 () 2 9 0 0 0 0 1
cytotoxicity measure. cytotoxicity c cy cyt cyto BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 ., 2 9 0 0 0 0 1
triplicate. triplicate. triplicate. t tr tri trip BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 . 1 1 0 0 0 0 1
NR uptake nr N NR NR NR BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 . 1 2 0 0 0 0 1
The NR the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 5 no 0 9 0 0 0 0 1
on the on o on on on BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 no 0 10 0 0 0 0 1
their lysosomes. their t th the thei BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 ., 2 9 0 1 0 0 1
yielding dependable yielding y yi yie yiel BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 no 0 9 0 1 0 0 1
in a in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 8 5 . 1 10 0 1 0 0 1
as an as a as as as BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 ,- 2 9 0 1 0 0 1
guish between guish g gu gui guis BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 ,,., 4 7 0 1 0 0 1
After exposure after A Af Aft Afte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 5 - 1 9 0 1 0 0 1
24 h, 24 2 24 24 24 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 5 , 1 9 0 1 0 0 1
NR (50 nr N NR NR NR BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 6 (/,),•, 7 10 0 0 0 0 1
humidified 5% humidified h hu hum humi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 -,. 3 9 0 0 0 0 1
incubation period, incubation i in inc incu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 ,, 2 8 0 0 0 0 1
washed with washed w wa was wash BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 (/) 3 8 0 0 0 0 1
extracted with extracted e ex ext extr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 /(:) 4 9 0 0 0 0 1
acetic acid. acetic a ac ace acet BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 6 . 1 9 0 0 0 0 1
plate reader plate p pl pla plat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 (,,). 5 8 0 0 0 0 1
percentage of percentage p pe per perc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 () 2 9 0 0 0 0 1
used as used u us use used BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 . 1 9 0 0 0 0 1
performed, in performed, p pe per perf BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 ,. 2 3 0 0 0 0 1
Quantification of quantification Q Qu Qua Quan BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 6 . 1 5 0 0 0 0 1
The potential the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 6 - 1 8 0 0 0 0 1
cellular levels cellular c ce cel cell BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 (), 3 9 0 0 0 0 1
induce oxidative induce i in ind indu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 , 1 9 0 0 0 0 1
cell permeant cell c ce cel cell BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 -(-)]. 6 9 0 0 0 0 1
entering the entering e en ent ente BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 ,- 2 9 0 0 0 0 1
DCFH. Subsequent dcfh. D DC DCF DCFH BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 6 . 1 9 0 0 0 0 1
of the of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 ,-()., 6 9 0 0 0 0 1
intensity of intensity i in int inte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 no 0 10 0 0 0 0 1
ROS levels, ros R RO ROS ROS BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 1 0 0 0 0 0 0 8 6 , 1 8 0 0 0 0 1
elevated ROS elevated e el ele elev BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 . 1 3 0 0 0 0 1
SH-SY5Y cells sh-sy5y S SH SH- SH-S BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 6 -- 2 8 0 0 0 0 1
dopaminergic differentiation dopaminergic d do dop dopa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 6 . 1 9 0 0 0 0 1
seeding, differentiated seeding, s se see seed BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 6 ,--- 4 9 0 0 0 0 1
(10 µM), (10 ( (1 (10 (10 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 6 (),,•,-. 8 9 0 0 0 0 1
Then, the then, T Th The Then BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 6 ,,- 3 9 0 0 0 0 1
pounds under pounds p po pou poun BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 8 6 (---).-(- 9 9 0 0 0 0 1
BHP, 100 bhp, B BH BHP BHP, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 6 ,,)- 4 8 0 0 0 0 1
production. After production. p pr pro prod BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 ., 2 9 0 0 0 0 1
measuring DCF measuring m me mea meas BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 ,( 2 9 0 0 0 0 1
BioTekInstruments, Vermont, biotekinstruments, B Bi Bio BioT BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 6 ,,), 4 9 0 0 0 0 1
485 nm 485 4 48 485 485 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 6 . 1 9 0 0 0 0 1
as percentage as a as as as BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 (). 3 6 0 0 0 0 1
Evaluation of evaluation E Ev Eva Eval BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 6 '. 2 7 0 0 0 0 1
The potential the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 6 no 0 8 0 0 0 0 1
were assessed were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 - 1 9 0 0 0 0 1
aggressors, such aggressors, a ag agg aggr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 ,---(, 6 9 0 0 0 0 1
metabolite of metabolite m me met meta BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 6 , 1 9 0 0 0 0 1
of Parkinson's of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 '),()[ 6 10 0 0 0 0 1
(III)-nitrilotriacetic acid (iii)-nitrilotriacetic ( (I (II (III BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 6 ()-()(), 8 9 0 0 0 0 1
overload]. overload]. overload]. o ov ove over BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 6 ]. 2 1 0 0 0 0 1
Protective Effects protective P Pr Pro Prot BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 6 -. 2 7 0 0 0 0 1
To evaluate to T To To To BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 6 no 0 9 0 0 0 0 1
MPP + mpp M MP MPP MPP BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 6 -,-( 4 9 0 0 0 0 1
25,000 cells/cm 25,000 2 25 25, 25,0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 8 6 ,/)- 4 9 0 0 0 0 1
differentiation, as differentiation, d di dif diff BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 ,., 3 10 0 0 0 0 1
stock solution stock s st sto stoc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 8 6 (/), 4 9 0 0 0 0 1
afterwards in afterwards a af aft afte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 6 no 0 9 0 0 0 0 1
and used and a an and and BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 .-- 3 8 0 0 0 0 1
exposed to exposed e ex exp expo BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 10 (,.,) 5 10 0 0 0 0 1
in fresh in i in in in BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 8 11 .-,( 4 10 0 0 0 0 1
and 1000 and a an and and BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 11 ),,•, 5 10 0 0 0 0 1
humidified 5% humidified h hu hum humi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 11 -,. 3 10 0 0 0 0 1
period, cell period, p pe per peri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 11 ,,- 3 10 0 0 0 0 1
viously described. viously v vi vio viou BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 11 .- 2 9 0 0 0 0 1
formed, in formed, f fo for form BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 11 ,. 2 3 0 0 0 0 1
Protective Effects protective P Pr Pro Prot BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 11 ()-. 4 8 0 0 0 0 1
The potential the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 11 ()- 3 9 0 0 0 0 1
induced cytotoxicity induced i in ind indu BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 11 - 1 9 0 0 0 0 1
J.L.P. Ribeiro j.l.p. J J. J.L J.L. BLOCKSTART PAGEEND NEWFONT LOWERFONT 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 11 .... 4 10 0 1 1 0 0
Bioorganic & bioorganic B Bi Bio Bioo BLOCKSTART PAGESTART NEWFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 () 2 10 0 1 1 0 0
10 10 10 1 10 10 10 BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 9 0 no 0 10 0 0 0 0 0
SY5Y cells sy5y S SY SY5 SY5Y BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 (). 3 8 0 1 0 0 1
solubilization of solubilization s so sol solu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 (),()- 6 10 0 1 0 0 1
NTA complex nta N NT NTA NTA BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ., 2 8 0 1 0 0 1
complex prevents complex c co com comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 () 2 9 0 1 0 0 1
been widely been b be bee been BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 8 0 1 0 0 1
Firstly, a firstly, F Fi Fir Firs BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 ,(,.) 5 8 0 1 0 0 1
Na 2 na N Na Na Na BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 9 0 ()() 4 8 0 1 0 0 1
pH = ph p pH pH pH BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 .,() 4 8 0 1 0 0 1
NTA solution, nta N NT NTA NTA BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ,.- 3 8 0 1 0 0 1
iment, a iment, i im ime imen BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 ,, 2 8 0 1 0 0 1
from light from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 no 0 8 0 1 0 0 1
complete formation complete c co com comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 no 0 8 0 1 0 0 1
cell cultures, cell c ce cel cell BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 , 1 9 0 1 0 0 1
desired concentrations. desired d de des desi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 3 0 1 0 0 1
Briefly, SH-SY5Y briefly, B Br Bri Brie BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 ,-,/ 4 8 0 1 0 0 1
and submitted and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 ,. 2 9 0 1 0 0 1
Six days six S Si Six Six BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 ,-- 3 9 0 1 0 0 1
the compounds the t th the the BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 1 (,.,), 6 10 0 0 0 0 1
culture medium. culture c cu cul cult BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 1 .-,( 4 10 0 0 0 0 1
1000 μM) 1000 1 10 100 1000 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 9 1 ),,•, 5 10 0 0 0 0 1
humidified 5% humidified h hu hum humi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 1 -,. 3 9 0 0 0 0 1
period, cell period, p pe per peri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 1 ,,- 3 9 0 0 0 0 1
viously described. viously v vi vio viou BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 1 .- 2 9 0 0 0 0 1
formed, in formed, f fo for form BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 1 ,. 2 3 0 0 0 0 1
Statistical Analysis. statistical S St Sta Stat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 1 . 1 3 0 0 0 0 1
The statistical the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 1 no 0 9 0 0 0 0 1
Windows (GraphPad windows W Wi Win Wind BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 1 (,).- 5 9 0 0 0 0 1
bution was bution b bu but buti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 1 -,' 3 8 0 0 0 0 1
Pearson omnibus, pearson P Pe Pea Pear BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 9 1 ,-. 3 9 0 0 0 0 1
compounds cytotoxicity, compounds c co com comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 1 ,- 2 8 0 0 0 0 1
statistical comparisons, statistical s st sta stat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 1 ,' 2 9 0 0 0 0 1
test. In test. t te tes test BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 1 .',- 4 9 0 0 0 0 1
way ANOVA way w wa way way BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 1 , 1 9 0 0 0 0 1
by the by b by by by BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 1 '., 3 10 0 0 0 0 1
than 0.05 than t th tha than BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 1 .. 2 5 0 0 0 0 1
CRediT authorship credit C CR CRe CRed BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 3 no 0 10 0 0 0 0 1
João L.P. joão J Jo Joã João BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ..:-,, 6 9 0 0 0 0 1
analysis. Inês analysis. a an ana anal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 .:-,. 5 9 0 0 0 0 1
Silva: Writing silva: S Si Sil Silv BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 :-,,. 5 10 0 0 0 0 1
M.M. Lopes: m.m. M M. M.M M.M. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 ..:-,,. 7 9 0 0 0 0 1
Lucília Saraiva: lucília L Lu Luc Lucí BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 :-,, 4 9 0 0 0 0 1
analysis, Conceptualization. analysis, a an ana anal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 ,....:- 7 9 0 0 0 0 1
review & review r re rev revi BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 ,,,. 4 9 0 0 0 0 1
Declaration of declaration D De Dec Decl BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 3 no 0 10 0 0 0 0 1
The authors the T Th The The BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 3 no 0 8 0 0 0 0 1
interests or interests i in int inte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 no 0 10 0 0 0 0 1
the work the t th the the BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 . 1 4 0 0 0 0 1
Data availability data D Da Dat Data BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 3 no 0 10 0 0 0 0 1
Data will data D Da Dat Data BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 3 . 1 10 0 0 0 0 1
Acknowledgements Acknowledgements acknowledgements A Ac Ack Ackn BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 3 no 0 10 0 0 0 0 1
The Coimbra the T Th The The BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 3 - 1 8 0 0 0 0 1
(CQC-IMS) and (cqc-ims) ( (C (CQ (CQC BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 3 (-)/- 5 8 0 0 0 0 1
dation for dation d da dat dati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 3 ()// 4 10 0 0 0 0 1
2020 (http://doi.org/10.54499/UIDB/00313/2020), 2020 2 20 202 2020 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 9 3 (://././//),// 14 8 0 0 0 0 1
2020 (http://doi.org/10.54499/UIDP/00313/2020), 2020 2 20 202 2020 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 9 3 (://././//),// 14 8 0 0 0 0 1
2020 (http://doi.org/10.54499/UIDP/50006/2020) 2020 2 20 202 2020 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 9 3 (://././//)// 13 9 0 0 0 0 1
2020 (http://doi.org/10.54499/UIDB/50006/2020) 2020 2 20 202 2020 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 9 3 (://././//)(), 14 9 0 0 0 0 1
and the and a an and and BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 (///,://././/// 15 9 0 0 0 0 1
2020) and 2020) 2 20 202 2020 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 4 )/(///,://./ 12 8 0 1 0 0 1
10.54499/LA/P/0008/2020) special 10.54499/la/p/0008/2020) 1 10 10. 10.5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 4 .////). 7 9 0 1 0 0 1
João L. joão J Jo Joã João BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 4 ..(///,) 8 8 0 1 0 0 1
and Susana and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 4 ..(///,://./ 12 9 0 1 0 0 1
10.54499/DL57/2016/CP1370/CT0057) also 10.54499/dl57/2016/cp1370/ct0057) 1 10 10. 10.5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 4 .////)- 7 9 0 1 0 0 1
vidual support. vidual v vi vid vidu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 4 ., 2 9 0 1 0 0 1
Sciences of sciences S Sc Sci Scie BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 4 , 1 9 0 1 0 0 1
national funds national n na nat nati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 4 -,.., 5 10 0 1 0 0 1
in the in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 4 //// 4 9 0 1 0 0 1
the Research the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 4 - 1 9 0 1 0 0 1
project LA/P/0140/2020 project p pr pro proj BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 4 /// 3 9 0 1 0 0 1
Health and health H He Hea Heal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 9 4 -.- 3 9 0 1 0 0 1
facility for facility f fa fac faci BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 4 (://../-/). 11 9 0 1 0 0 1
Appendix A. appendix A Ap App Appe BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 5 . 1 10 0 0 0 0 1
Supplementary data supplementary S Su Sup Supp BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 5 ://. 4 10 0 0 0 0 1
org/10.1016/j.bmc.2024.117841. org/10.1016/j.bmc.2024.117841. org/10.1016/j.bmc.2024.117841. o or org org/ BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 5 /./.... 7 4 0 0 0 0 1
References References references R Re Ref Refe BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 6 no 0 10 0 0 0 0 1
1. Zulkifli 1. 1 1. 1. 1. BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,,,,. 6 9 0 0 0 0 1
biological activities biological b bi bio biol BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 6 -:..: 5 9 0 0 0 0 1
1-14. https://doi.org/10.1080/14786419.2023.2261141. 1-14. 1 1- 1-1 1-14 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 -.://././... 12 5 0 0 0 0 1
2. Abinaya 2. 2 2. 2. 2. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,,,,,. 7 8 0 0 0 0 1
Recent developments recent R Re Rec Rece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 6 , 1 9 0 0 0 0 1
β-carboline derivatives β-carboline β β- β-c β-ca BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 6 --..;,.://. 11 9 0 0 0 0 1
org/10.1016/j.molstruc.2022.132750. org/10.1016/j.molstruc.2022.132750. org/10.1016/j.molstruc.2022.132750. o or org org/ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 6 /./.... 7 4 0 0 0 0 1
3. Ashok 3. 3 3. 3. 3. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,-,,-,.,, 10 8 0 0 0 0 1
biological evaluation biological b bi bio biol BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 6 -(--)--[,-] 11 9 0 0 0 0 1
Anti-HIV-1 agents. anti-hiv-1 A An Ant Anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 --..;:-.://././ 15 9 0 0 0 0 1
cbdd.12456. cbdd.12456. cbdd.12456. c cb cbd cbdd BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 6 .. 2 1 0 0 0 0 1
4. Kushwaha 4. 4 4. 4. 4. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,,.- 5 8 0 0 0 0 1
potential antimalarial potential p po pot pote BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 6 ..;,.://. 9 9 0 0 0 0 1
org/10.1016/j.ejmech.2023.115247. org/10.1016/j.ejmech.2023.115247. org/10.1016/j.ejmech.2023.115247. o or org org/ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 6 /./.... 7 3 0 0 0 0 1
5. Pontes 5. 5 5. 5. 5. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,-,,.: 7 9 0 0 0 0 1
current and current c cu cur curr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 6 ..;:-.://. 10 9 0 0 0 0 1
org/10.1016/j.drudis.2021.07.009. org/10.1016/j.drudis.2021.07.009. org/10.1016/j.drudis.2021.07.009. o or org org/ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 6 /./..... 8 3 0 0 0 0 1
6. Panice 6. 6 6. 6. 6. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,,,.--- 8 9 0 0 0 0 1
β-carboline-3-carboxylates with β-carboline-3-carboxylates β β- β-c β-ca BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 ----..;: 8 8 0 0 0 0 1
123-132. https://doi.org/10.1016/j.ejmech.2019.05.085. 123-132. 1 12 123 123- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 -.://././..... 14 6 0 0 0 0 1
7. Ribeiro 7. 7 7. 7. 7. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,,,,.-(,,--- 13 9 0 0 0 0 1
yl)-β-carbolines and yl)-β-carbolines y yl yl) yl)- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 6 )---(---)--: 12 9 0 0 0 0 1
anticancer agents. anticancer a an ant anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 6 ..;:.://././ 12 8 0 0 0 0 1
ph15121510. ph15121510. ph15121510. p ph ph1 ph15 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 6 . 1 1 0 0 0 0 1
8. Aaghaz 8. 8 8. 8. 8. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,,,.-. 7 9 0 0 0 0 1
Eur J eur E Eu Eur Eur BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 6 .;,.://././. 12 6 0 0 0 0 1
ejmech.2021.113321. ejmech.2021.113321. ejmech.2021.113321. e ej ejm ejme BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 6 ... 3 2 0 0 0 0 1
9. Tshikhudo 9. 9 9. 9. 9. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,,,. 5 8 0 0 0 0 1
β-carboline alkaloids: β-carboline β β- β-c β-ca BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 6 -:..;: 6 9 0 0 0 0 1
e202301263. e202301263. e202301263. e e2 e20 e202 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 6 . 1 1 0 0 0 0 1
10. Beato 10. 1 10 10. 10. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,,,,.- 7 8 0 0 0 0 1
privileged scaffold privileged p pr pri priv BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 6 '. 2 9 0 0 0 0 1
Chem. 2021;64:1392-1422. chem. C Ch Che Chem BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 6 .;:-.://././... 15 7 0 0 0 0 1
11. Ayipo 11. 1 11 11. 11. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,,,. 5 9 0 0 0 0 1
of β-carboline of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 6 -..;, 5 9 0 0 0 0 1
173837. https://doi.org/10.1016/j.ejphar.2020.173837. 173837. 1 17 173 1738 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 6 .://././.... 12 6 0 0 0 0 1
12. Louis 12. 1 12 12. 12. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,,,-,. 7 9 0 0 0 0 1
(1-methyl-9H-pyrido[3,4-b]indole) concentrations (1-methyl-9h-pyrido[3,4-b]indole) ( (1 (1- (1-m BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 (---[,-])'. 11 8 0 0 0 0 1
Neurotoxicology. 2014;40:52-56. neurotoxicology. N Ne Neu Neur BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 6 .;:-.://././..... 17 8 0 0 0 0 1
13. Piechowska 13. 1 13 13. 13. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,-,-.- 7 9 0 0 0 0 1
food: a food: f fo foo food BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 6 :..;:.://././. 14 8 0 0 0 0 1
14. Szabó 14. 1 14 14. 14. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,,.-. 6 10 0 0 0 0 1
Molecules. 2021;26:663. molecules. M Mo Mol Mole BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 6 .;:.://././. 12 7 0 0 0 0 1
15. Mousa 15. 1 15 15. 15. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,,,-.- 7 9 0 0 0 0 1
β-carboline synthesis β-carboline β β- β-c β-ca BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 6 -..;:. 6 9 0 0 0 0 1
16. Lopes 16. 1 16 16. 16. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,,,. 5 9 0 0 0 0 1
of conjugated of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 6 ..;:-. 6 8 0 0 0 0 1
https://doi.org/10.1021/acs.chemrev.8b00375. https://doi.org/10.1021/acs.chemrev.8b00375. https://doi.org/10.1021/acs.chemrev.8b00375. h ht htt http BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 1 9 6 ://././... 10 5 0 0 0 0 1
17. Lopes 17. 1 17 17. 17. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,,.-- 6 9 0 0 0 0 1
1H-tetrazoles: synthesis 1h-tetrazoles: 1 1H 1H- 1H-t BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 -:-,-,--(-)- 12 9 0 0 0 0 1
1H-tetrazoles. Tetrahedron 1h-tetrazoles. 1 1H 1H- 1H-t BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 -..;:-.://././. 15 8 0 0 0 0 1
tetlet.2010.10.095. tetlet.2010.10.095. tetlet.2010.10.095. t te tet tetl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 6 .... 4 2 0 0 0 0 1
18. Lopes 18. 1 18 18. 18. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,,,.--(-- 10 9 0 0 0 0 1
5-yl)-nitrosoalkenes: synthesis 5-yl)-nitrosoalkenes: 5 5- 5-y 5-yl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 -)-:-()--. 10 9 0 0 0 0 1
Tetrahedron. 2011;67:8902-8909. tetrahedron. T Te Tet Tetr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 6 .;:-.://././..... 17 8 0 0 0 0 1
19. Lopes 19. 1 19 19. 19. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,,,,.-- 8 9 0 0 0 0 1
nitrosoethylenes towards nitrosoethylenes n ni nit nitr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 6 ..;:-. 6 8 0 0 0 0 1
https://doi.org/10.1007/s00706-016-1763-1. https://doi.org/10.1007/s00706-016-1763-1. https://doi.org/10.1007/s00706-016-1763-1. h ht htt http BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 1 9 6 ://././---. 11 4 0 0 0 0 1
J.L.P. Ribeiro j.l.p. J J. J.L J.L. BLOCKSTART PAGEEND NEWFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 10 11 .... 4 10 0 1 1 0 0
Bioorganic & bioorganic B Bi Bio Bioo BLOCKSTART PAGESTART NEWFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 0 () 2 10 0 1 1 0 0
11 11 11 1 11 11 11 BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 10 0 no 0 10 0 0 0 0 0
20. Aaseth 20. 2 20 20. 20. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,,.'. 6 9 0 1 0 0 1
Biometals. 2018;31:737-747. biometals. B Bi Bio Biom BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 0 .;:-.://././---. 16 7 0 1 0 0 1
21. Liu 21. 2 21 21. 21. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .-,-,-,. 8 8 0 1 0 0 1
onto basoamygdala onto o on ont onto BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 ..;:-. 6 8 0 1 0 0 1
https://doi.org/10.1016/j.brainresbull.2018.01.004. https://doi.org/10.1016/j.brainresbull.2018.01.004. https://doi.org/10.1016/j.brainresbull.2018.01.004. h ht htt http BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 1 10 0 ://././..... 12 5 0 1 0 0 1
22. Ebrahimi-Ghiri 22. 2 22 22. 22. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .-,,-. 6 9 0 1 0 0 1
of ACPA of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 -..;:-.:// 10 8 0 1 0 0 1
doi.org/10.1016/j.bbr.2019.02.034. doi.org/10.1016/j.bbr.2019.02.034. doi.org/10.1016/j.bbr.2019.02.034. d do doi doi. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 0 ././..... 9 3 0 1 0 0 1
23. Morales-García 23. 2 23 23. 23. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .-,,-,. 7 9 0 1 0 0 1
Banisteriopsis caapi, banisteriopsis B Ba Ban Bani BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 0 ,, 2 8 0 1 0 0 1
stimulate adult stimulate s st sti stim BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 ..;:.://./ 10 8 0 1 0 0 1
10.1038/s41598-017-05407-9. 10.1038/s41598-017-05407-9. 10.1038/s41598-017-05407-9. 1 10 10. 10.1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 0 ./---. 6 3 0 1 0 0 1
24. Mohamad 24. 2 24 24. 24. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,,,., 6 9 0 1 0 0 1
crystal structure crystal c cr cry crys BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 10 0 --. 3 9 0 1 0 0 1
J Mol j J J J J BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 10 0 .;,.://././.... 15 9 0 1 0 0 1
25. Guo 25. 2 25 25. 25. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,,,. 5 10 0 1 0 0 1
on Alzheimer's on o on on on BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 '..;,.:// 9 9 0 1 0 0 1
doi.org/10.1016/j.bioorg.2019.103258. doi.org/10.1016/j.bioorg.2019.103258. doi.org/10.1016/j.bioorg.2019.103258. d do doi doi. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 0 ././.... 8 4 0 1 0 0 1
26. Zhao 26. 2 26 26. 26. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,,,., 6 9 0 1 0 0 1
β-carboline derivatives β-carboline β β- β-c β-ca BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 0 -' 2 9 0 1 0 0 1
disease. Bioorg disease. d di dis dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 ..;:-.://././. 14 8 0 1 0 0 1
bmc.2018.06.018. bmc.2018.06.018. bmc.2018.06.018. b bm bmc bmc. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 0 .... 4 1 0 1 0 0 1
27. Aricioglu 27. 2 27 27. 27. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,,,. 5 9 0 1 0 0 1
threshold in threshold t th thr thre BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 ..;:-. 6 8 0 1 0 0 1
https://doi.org/10.1196/annals.1304.023. https://doi.org/10.1196/annals.1304.023. https://doi.org/10.1196/annals.1304.023. h ht htt http BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 1 10 0 ://././... 10 4 0 1 0 0 1
28. Kasteleijn-Nolst 28. 2 28 28. 28. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .-,,,. 6 9 0 1 0 0 1
efficacy evaluation efficacy e ef eff effi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 no 0 9 0 1 0 0 1
epilepsy patients: epilepsy e ep epi epil BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 :-..;:-. 8 9 0 1 0 0 1
https://doi.org/10.1016/j.eplepsyres.2016.02.003. https://doi.org/10.1016/j.eplepsyres.2016.02.003. https://doi.org/10.1016/j.eplepsyres.2016.02.003. h ht htt http BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 1 10 0 ://././..... 12 5 0 1 0 0 1
29. Wernicke 29. 2 29 29. 29. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,,,.--- 8 9 0 1 0 0 1
in an in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 10 0 '..;:-.:// 10 9 0 1 0 0 1
doi.org/10.1016/S1734-1140(10)70241-3. doi.org/10.1016/S1734-1140(10)70241-3. doi.org/10.1016/s1734-1140(10)70241-3. d do doi doi. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 0 ././-()-. 9 4 0 1 0 0 1
30. Samoylenko 30. 3 30 30. 30. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,,,., 6 8 0 1 0 0 1
combination of combination c co com comb BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 no 0 8 0 1 0 0 1
relevant to relevant r re rel rele BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 '.. 3 9 0 1 0 0 1
2010;127:357-367. https://doi.org/10.1016/j.jep.2009.10.030. 2010;127:357-367. 2 20 201 2010 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 0 ;:-.://././..... 16 6 0 1 0 0 1
31. Zawirska-Wojtasiak 31. 3 31 31. 31. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .-,-,,.- 8 9 0 1 0 0 1
experiments on experiments e ex exp expe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 ..;:.://./ 10 9 0 1 0 0 1
10.3390/ijms21155245. 10.3390/ijms21155245. 10.3390/ijms21155245. 1 10 10. 10.3 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 0 ./. 3 2 0 1 0 0 1
32. O'Brien 32. 3 32 32. 32. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .',,,.() 8 9 0 1 0 0 1
fluorescent dye fluorescent f fl flu fluo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 .. 2 9 0 1 0 0 1
2000;267:5421-5426. https://doi.org/10.1046/j.1432-1327.2000.01606.x. 2000;267:5421-5426. 2 20 200 2000 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 6 ;:-.://././.-.... 17 7 0 1 0 0 1
33. Präbst 33. 3 33 33. 33. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,,,. 5 9 0 1 0 0 1
assays: MTT, assays: a as ass assa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 :,,..;:-.://. 13 8 0 1 0 0 1
org/10.1007/978-1-4939-6960-9_1. org/10.1007/978-1-4939-6960-9_1. org/10.1007/978-1-4939-6960-9_1. o or org org/ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 6 /./----. 8 3 0 1 0 0 1
34. Repetto 34. 3 34 34. 34. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,,. 4 9 0 1 0 0 1
viability/cytotoxicity. Nat viability/cytotoxicity. v vi via viab BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 6 /..;:-.://././ 14 8 0 1 0 0 1
nprot.2008.75. nprot.2008.75. nprot.2008.75. n np npr npro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 6 ... 3 1 0 1 0 0 1
35. Zuang 35. 3 35 35. 35. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 ..:..;:-. 9 9 0 1 0 0 1
https://doi.org/10.1177/026119290102900513. https://doi.org/10.1177/026119290102900513. https://doi.org/10.1177/026119290102900513. h ht htt http BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 1 11 6 ://././. 8 4 0 1 0 0 1
36. I. 36. 3 36 36. 36. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 ..,: 4 9 0 1 0 0 1
toxicological profile toxicological t to tox toxi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 ., 2 9 0 1 0 0 1
University of university U Un Uni Univ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 6 . 1 2 0 1 0 0 1
37. Jiang 37. 3 37 37. 37. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,,,.,-, 8 9 0 1 0 0 1
nitrilotriacetic acid: nitrilotriacetic n ni nit nitr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 6 :,,- 4 9 0 1 0 0 1
induced oxidative induced i in ind indu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 '..;:-. 7 9 0 1 0 0 1
https://doi.org/10.1021/bi900907a. https://doi.org/10.1021/bi900907a. https://doi.org/10.1021/bi900907a. h ht htt http BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 1 11 6 ://././. 8 3 0 1 0 0 1
38. Mustapha 38. 3 38 38. 38. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,.-': 6 8 0 1 0 0 1
promising direction promising p pr pro prom BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 ..;: 4 8 0 1 0 0 1
422-433. https://doi.org/10.17305/bjbms.2020.5181. 422-433. 4 42 422 422- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 -.://././... 12 5 0 1 0 0 1
39. Schmidt 39. 3 39 39. 39. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,.' 4 8 0 1 0 0 1
disease. J disease. d di dis dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 ..;:-.://././ 13 7 0 1 0 0 1
s007020100004. s007020100004. s007020100004. s s0 s00 s007 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 6 . 1 1 0 1 0 0 1
40. Yan 40. 4 40 40. 40. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,,,. 5 9 0 1 0 0 1
inhibiting autophagy inhibiting i in inh inhi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 --....-.; 9 9 0 1 0 0 1
28:6. https://doi.org/10.1186/s40709-021-00137-6. 28:6. 2 28 28: 28:6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 :.://././---. 13 5 0 1 0 0 1
41. Costa 41. 4 41 41. 41. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,,,. 5 9 0 1 0 0 1
involvement in involvement i in inv invo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 ..;,.://./ 10 9 0 1 0 0 1
10.1016/j.pharmthera.2023.108373. 10.1016/j.pharmthera.2023.108373. 10.1016/j.pharmthera.2023.108373. 1 10 10. 10.1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 6 ./.... 6 3 0 1 0 0 1
42. Weinreb 42. 4 42 42. 42. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,,,. 5 9 0 1 0 0 1
homeostasis in homeostasis h ho hom home BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 6 '..;: 5 9 0 1 0 0 1
52-64. https://doi.org/10.1016/j.freeradbiomed.2013.01.017. 52-64. 5 52 52- 52-6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 -.://././..... 14 6 0 1 0 0 1
43. Kovalevich 43. 4 43 43. 43. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,.- 4 9 0 1 0 0 1
cells in cells c ce cel cell BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 ..;:-.://././ 13 9 0 1 0 0 1
978-1-62703-640-5_2. 978-1-62703-640-5_2. 978-1-62703-640-5_2. 9 97 978 978- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 6 ----. 5 2 0 1 0 0 1
44. Barbosa 44. 4 44 44. 44. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,,,."" 7 10 0 1 0 0 1
toxic to toxic t to tox toxi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 -. 2 9 0 1 0 0 1
Toxicol. 2014;88:455-473. toxicol. T To Tox Toxi BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 6 .;:-.://././---. 16 7 0 1 0 0 1
J.L.P. Ribeiro j.l.p. J J. J.L J.L. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 11 11 .... 4 10 0 1 1 0 0

